Avidity Biosciences Statistics
Share Statistics
Avidity Biosciences has 119.31M shares outstanding. The number of shares has increased by 49.66% in one year.
| Shares Outstanding | 119.31M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 1.87% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 108.37M |
| Failed to Deliver (FTD) Shares | 191 |
| FTD / Avg. Volume | 0.02% |
Short Selling Information
The latest short interest is 15.48M, so 12.97% of the outstanding shares have been sold short.
| Short Interest | 15.48M |
| Short % of Shares Out | 12.97% |
| Short % of Float | 14.26% |
| Short Ratio (days to cover) | 12.09 |
Valuation Ratios
The PE ratio is -3.11 and the forward PE ratio is -15.52.
| PE Ratio | -3.11 |
| Forward PE | -15.52 |
| PS Ratio | 69.12 |
| Forward PS | 147.1 |
| PB Ratio | 1.32 |
| P/FCF Ratio | -5.36 |
| PEG Ratio | n/a |
Enterprise Valuation
Avidity Biosciences Inc. has an Enterprise Value (EV) of 485.53M.
| EV / Earnings | -2.29 |
| EV / Sales | 50.79 |
| EV / EBITDA | -2.08 |
| EV / EBIT | -2.06 |
| EV / FCF | -3.94 |
Financial Position
The company has a current ratio of 7.58, with a Debt / Equity ratio of 0.02.
| Current Ratio | 7.58 |
| Quick Ratio | 7.58 |
| Debt / Equity | 0.02 |
| Total Debt / Capitalization | 2.19 |
| Cash Flow / Debt | -10.63 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.42% and return on capital (ROIC) is -46.14%.
| Return on Equity (ROE) | -0.42% |
| Return on Assets (ROA) | -0.34% |
| Return on Capital (ROIC) | -46.14% |
| Revenue Per Employee | 37.79K |
| Profits Per Employee | -838.81K |
| Employee Count | 253 |
| Asset Turnover | 0.02 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 148.3% in the last 52 weeks. The beta is 0.91, so Avidity Biosciences 's price volatility has been higher than the market average.
| Beta | 0.91 |
| 52-Week Price Change | 148.3% |
| 50-Day Moving Average | 37.84 |
| 200-Day Moving Average | 37.62 |
| Relative Strength Index (RSI) | 28.03 |
| Average Volume (20 Days) | 1.17M |
Income Statement
In the last 12 months, Avidity Biosciences had revenue of 9.56M and earned -212.22M in profits. Earnings per share was -2.91.
| Revenue | 9.56M |
| Gross Profit | 7.46M |
| Operating Income | -235.60M |
| Net Income | -212.22M |
| EBITDA | -233.50M |
| EBIT | -235.60M |
| Earnings Per Share (EPS) | -2.91 |
Balance Sheet
The company has 185.08M in cash and 9.85M in debt, giving a net cash position of 175.23M.
| Cash & Cash Equivalents | 185.08M |
| Total Debt | 9.85M |
| Net Cash | 175.23M |
| Retained Earnings | -570.76M |
| Total Assets | 1.64B |
| Working Capital | 1.53B |
Cash Flow
In the last 12 months, operating cash flow was -119.06M and capital expenditures -4.23M, giving a free cash flow of -123.29M.
| Operating Cash Flow | -119.06M |
| Capital Expenditures | -4.23M |
| Free Cash Flow | -123.29M |
| FCF Per Share | -1.69 |
Margins
Gross margin is 78.02%, with operating and profit margins of -2.46K% and -2.22K%.
| Gross Margin | 78.02% |
| Operating Margin | -2.46K% |
| Pretax Margin | -2.22K% |
| Profit Margin | -2.22K% |
| EBITDA Margin | -2.44K% |
| EBIT Margin | -2.46K% |
| FCF Margin | -1.29K% |
Dividends & Yields
RNA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -10.78% |
| FCF Yield | -3.83% |
Analyst Forecast
The average price target for RNA is $63, which is 133.4% higher than the current price. The consensus rating is "Buy".
| Price Target | $63 |
| Price Target Difference | 133.4% |
| Analyst Consensus | Buy |
| Analyst Count | 10 |
Scores
| Altman Z-Score | 16.2 |
| Piotroski F-Score | 4 |